New data point to broad label for Tesaro's niraparib

Tesaro Inc. (NASDAQ:TSRO) rose $18.64 (19%) to $117.90 on Monday after it revealed full data from the Phase III NOVA study of niraparib ( MK-4827) that could support the candidate's approval to treat ovarian cancer regardless of gene mutation status. Tesaro has already begun submitting a rolling NDA for the PARP inhibitor, and plans to submit an MAA to EMA this quarter.

Monday's gains pushed the company's market cap above $6 billion, and shares touched an intraday 52-week high of $122.89. ...